Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc. reports developments from its oncology business, including commercial performance for the cabozantinib franchise and clinical and regulatory updates across cancer programs. The company discovers, develops and commercializes cancer medicines, with CABOMETYX® (cabozantinib) as its flagship commercial product and COMETRIQ® also part of its cabozantinib portfolio.
Recurring updates include quarterly financial results, product revenue trends, financial guidance, pipeline milestones and investor conference presentations. Exelixis also discusses zanzalintinib, an investigational oral kinase inhibitor, and a broader pipeline of small molecules and biotherapeutics targeting additional tumor types and indications.
Exelixis (Nasdaq: EXEL) reported Q1 2026 revenues of $610.8M, including cabozantinib U.S. net product revenues of $555.0M. GAAP diluted EPS was $0.79 and non-GAAP diluted EPS was $0.87. The company announced a new $750M stock repurchase program through end of 2027 and an FDA PDUFA date of Dec 3, 2026 for zanzalintinib.
Guidance for 2026 is maintained with total revenue guidance of $2.525B–$2.625B and R&D guidance of $875M–$925M.
Exelixis (Nasdaq: EXEL) will release its first quarter 2026 financial results on Tuesday, May 5, 2026 after the market close. Management will host a conference call and live webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT.
Access is available via the company website Event Calendar under Investors & News; a replay will be archived for one year.
Exelixis (Nasdaq: EXEL) will webcast management fireside chats at four investor conferences in March. Presentations are scheduled on March 3, March 10 and March 11 with session times listed in ET and PT.
Webcasts and replays will be available via the company website Event Calendar under Investors & News, with replays accessible for at least 30 days.
Exelixis (Nasdaq: EXEL) reported Q4 2025 total revenues $598.7M and FY2025 total revenues $2.320B. U.S. cabozantinib net product revenues were $546.6M (Q4) and $2.123B (FY). GAAP diluted EPS was $0.88 (Q4) and $2.78 (FY). The FDA accepted the NDA for zanzalintinib with a PDUFA date of Dec 3, 2026. FY2026 guidance: total revenues $2.525B–$2.625B, net product revenues $2.325B–$2.425B, R&D $875M–$925M, SG&A $575M–$625M.
Exelixis (Nasdaq: EXEL) announced that the U.S. FDA accepted its New Drug Application for zanzalintinib combined with atezolizumab for previously treated metastatic colorectal cancer.
The FDA set a standard review PDUFA target action date of December 3, 2026. The NDA is supported by phase 3 STELLAR-303, which showed a statistically significant overall survival benefit versus regorafenib in the intention-to-treat population; some endpoint data remain immature with a planned final analysis expected in mid-2026.
Exelixis (Nasdaq: EXEL) will release fourth quarter and fiscal year 2025 financial results on Tuesday, February 10, 2026 after market close. Management will host a conference call and live webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT to discuss results and provide a business update.
Access is available via the company website Event Calendar under Investors & News; registrants for the call receive a dial-in number and unique PIN. A webcast replay will be archived on the website for one year.
Exelixis (Nasdaq: EXEL) reported preliminary unaudited fiscal 2025 results and issued 2026 guidance. Key figures include cabozantinib U.S. net product revenues of ~$2.123 billion for FY2025 and FY2026 net product revenue guidance of $2.325–$2.425 billion (assumes a 3.0% U.S. WAC increase). Fiscal 2025 R&D was ~$825 million and FY2026 R&D guidance is $875–$925 million. Ending cash and marketable securities were ~$1.65 billion. The company highlighted multiple mid-2026 clinical readouts for zanzalintinib and ongoing pivotal trials, plus an additional $750 million share repurchase authorization.
Summary not available.
Exelixis (NASDAQ: EXEL) announced that Michael M. Morrissey, Ph.D., president and CEO, will provide a corporate overview at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. PT / 8:15 p.m. ET.
The presentation will be webcast and accessible via www.exelixis.com under the Event Calendar on the Investors & News page. A replay will be available at the same location for at least 30 days.
Exelixis (NASDAQ: EXEL) will webcast a virtual 2025 R&D Day titled Building Next-generation Oncology Franchises on Wednesday, December 10, 2025 from 1:00 p.m. to 3:30 p.m. EST. Featured speakers will review Exelixis' R&D progress and outline the company strategy to advance future oncology franchises, with a focus on raising standards of care and generating long-term shareholder value.
The live webcast and a recording will be available at EXELRDDay.com and on the company Event Calendar at exelixis.com under Investors & News; content will remain accessible for one year. Registration uses code EXELR&D; participants are encouraged to register in advance for timely access.